A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer.

Trial Profile

A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Topotecan (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Mar 2013 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Jul 2002 to Aug 2002 as reported by Clinicaltrials.gov
    • 05 Jul 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top